September 2014

New Product - Mirvaso

Mirvaso (brimonidine) contains a selective α2-adrenergic receptor agonist that is 1000-fold more selective for the α2-adrenergic receptor than the α1-adrenergic receptor. Topical facial application of a highly selective α2-adrenergic receptor agonist is intended to reduce erythema through direct cutaneous vasoconstriction. Mirvaso is indicated for the treatment of facial erythema of rosacea in adults. It is contraindicated in children under 18 years of age; therapy with concomitant monoamine oxidase inhibitor (MAOI) and with tricyclic or tetracyclic antidepressants, which affect noradrenergic transmission. Mirvaso is available as a gel containing brimonidine tartrate 5 mg/g (≡ brimonidine 3.3 mg/g) in a 30 g tube in packs of 1’s.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629